Opthea strengthens its Board of Directors
April 22, 2022 08:15 ET
|
Opthea Limited
MELBOURNE, Australia, April 22, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea To Present at Oppenheimer’s 32nd Annual Healthcare Conference
March 10, 2022 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, March 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive...
Opthea Expands Leadership Team with the Appointment of Joel Naor, M.D., M.Sc., MBA as Chief Medical Officer
March 02, 2022 06:00 ET
|
Opthea Limited
Key appointment as Opthea progresses the Phase 3 clinical development of OPT-302 in wet AMD MELBOURNE, Australia, March 02, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical...
Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022
February 14, 2022 06:00 ET
|
Opthea Limited
Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea’s Phase 2b clinical trial of OPT-302 in combination with...
Opthea To Present at SVB Leerink Global Healthcare Conference
February 10, 2022 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference
February 09, 2022 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Receives A$6.6 m R&D Tax Incentive
January 24, 2022 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea To Present at H.C. Wainwright BIOCONNECT Virtual Conference
January 04, 2022 06:18 ET
|
Opthea Limited
MELBOURNE, Australia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive...
Opthea Appoints Chief Commercial Officer to Lead Commercialization of OPT-302 for Wet AMD
January 03, 2022 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Granted Chinese Patent Covering OPT-302
October 26, 2021 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...